Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Anticancer Drugs
; 29(4): 287-294, 2018 04.
Article
em En
| MEDLINE
| ID: mdl-29420335
ABSTRACT
The issue of induction chemotherapy (ICT) interest in locoregionally advanced squamous cell cancer of the head and neck is a real epic that has been carried out over four phase III studies PARADIGM, DECIDE, NCT01086826 and lastly the conclusive GORTEC 2007-02. With no significant benefit in overall survival of ICT, followed by concurrent chemoradiation over the standard chemoradiotherapy alone, in three of these studies, and a significant number of treatment-related deaths with the standard regimen docetaxel, cisplatin, and fluorouracil, ICT is no longer a hot topic. However, this strategy might still be useful in the aim of limiting the metastatic extension affecting up to 30% of patients ICT is systematically associated with a reduced metastatic relapse even though the survival effect is never statistically significant when compared directly with concomitant radiochemotherapy. This review summarizes the major studies with their limits and discusses how the ICT could improve the patients' prognosis in the future.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quimiorradioterapia
/
Quimioterapia de Indução
/
Carcinoma de Células Escamosas de Cabeça e Pescoço
/
Neoplasias de Cabeça e Pescoço
/
Recidiva Local de Neoplasia
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article